Bimodal action of furosemide on convulsant [3H]EBOB binding to cerebellar and cortical GABA(A) receptors

Neurochemistry International

Volumn 33, Issue 4, 1998, Pages 353-358

  Maksay, Gábor ^a   Finland, ^a   Korpi, Esa R ^b   Uusi Oukari, Mikko ^b  

^a CTRL RES INSTITUTE FOR CHEMISTRY   (Hungary)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Cerebellum; Convulsant (EBOB) binding; Furosemide; GABA(A) receptor; Niflumate; Pentobarbital

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; CHLORIDE ION; CONVULSANT AGENT; FUROSEMIDE; NIFLUMIC ACID; PENTOBARBITAL; PICROTOXIN; RECEPTOR SUBTYPE;

ALLOSTERISM; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; BINDING SITE; BRAIN CORTEX; CEREBELLUM; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DENSITY;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CEREBELLUM; CEREBRAL CORTEX; CHLORIDES; CONVULSANTS; FUROSEMIDE; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; KINETICS; NIFLUMIC ACID; PENTOBARBITAL; RATS; RATS, WISTAR; RECEPTORS, GABA-A;

ANIMALIA;

EID: 0032191136     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(98)00038-2     Document Type: Article

References (24)

1. Cole L.M., Casida J.E. Pestic. Biochem. Physiol. 44:1992;1-8.
2. Concas A., Santoro G., Mascia M.P., Maciocco E., Dazzi L., Biggio G. Eur. J. Pharmacol. 267:1994;207-213.
3. Evoniuk G., Skolnick P. Mol. Pharmacol. 34:1988;837-842.
4. Fisher J.L., Zhang J., Macdonald R.L. Mol. Pharmacol. 52:1997;714-724.
5. Havoundjian H., Paul S.M., Skolnick P. Proc. Natl. Acad. Sci. USA. 80:1986;9241-9244.
6. Huang J., Casida J.E. J. Pharmacol. Exp. Ther. 281:1997;261-266.
7. Karle J., Witt M.-R., Nielsen M. Neurochem. Int. 31:1997;437-446.
8. Knoflach F., Benke D., Wang Y., Scheurer L., Lüddens H., Hamilton B.J., Carter D.B., Möhler H., Benson J.A. Mol. Pharmacol. 50:1996;1253-1261.
9. Korpi E.R., Kuner T., Seeburg P.H., Lüddens H. Mol. Pharmacol. 47:1995;283-289.
10. Korpi E.R., Lüddens H. Br. J. Pharmacol. 120:1997;741-748.
11. Not available.
12. Kume A., Albin R.L. Eur. J. Pharmacol. 263:1994;163-173.
13. Liljequist S., Tabakoff B. Life Sci. 39:1986;851-855.
14. Liljequist S., Tabakoff B. J. Pharmacol. Exp. Ther. 264:1993;638-647.
15. Maksay G. Neurochem. Int. 29:1996;361-370.
16. Maksay G., Simonyi M. Mol. Pharmacol. 30:1986;321-328.
17. Maksay G., van Rijn C.M. J. Neurochem. 61:1993;2081-2088.
18. Mäkelä R., Lehtonen M., Wisden W., Lüddens H., Korpi E.R. Neuropharmacology. 35:1996;1493-1502.
19. Squires R.F., Casida J.E., Richardson M., Saederup E. Mol. Pharmacol. 23:1983;326-336.
20. Squires R.F., Saederup E. Brain Res. 414:1987;357-364.
21. Sieghart W. Pharmacol. Rev. 47:1995;181-234.
22. Supavilai P., Karobath M. J. Neurosci. 4:1984;1193-1200.
23. Thomas G.J., Harper C.G., Dodd P.R. Neurochem. Int. 32:1998;375-385.
24. Ticku M.K., Ramanjaneyulu R. Pharmacol. Biochem. Behav. 21:1984;151-158.